Major histocompatibility complex class I alpha 3 domain (MHC I α3) (MHC I α3)

The Major histocompatibility complex (MHC) class I alpha 3 (α3) domain is a highly conserved, non-polymorphic region of the MHC class I heavy chain that plays a pivotal role in the adaptive immune system. Its primary biological function is to serve as the essential binding site for the CD8 co-receptor found on the surface of cytotoxic T lymphocytes (CTLs). This interaction stabilizes the ternary complex between the T-cell receptor (TCR), the peptide-MHC, and the CD8 molecule, which is necessary for efficient signal transduction and subsequent T-cell activation (PMID: 10880518). In oncology, the α3 domain is a focal point for developing next-generation immunotherapies, such as bispecific T-cell engagers and engineered TCRs, which aim to bypass or enhance the natural CD8-MHC interaction to overcome tumor-induced immune evasion (PMID: 28430612). Conversely, in the context of transplantation and autoimmunity, targeting this domain with inhibitory agents can potentially suppress unwanted T-cell-mediated tissue damage. Therapeutic strategies often involve engineering molecules that bind to the peptide-MHC complex while maintaining or optimizing the recruitment of CD8+ T cells via this domain. Therapeutic challenges include the risk of systemic cytokine release and the potential for broad immune suppression due to the ubiquitous expression of MHC class I molecules across nucleated cells. Monitoring HLA expression levels and CD8+ T-cell infiltration are critical for assessing the efficacy and safety of drugs targeting this site.

Other names

CD8 binding site on MHC IHLA class I alpha 3 domainMHC-I a3 domainMHC class I α3 domainMHC I heavy chain alpha 3 domain

Modulation of the CD8 co-receptor interaction with the MHC class I complex to either enhance or inhibit cytotoxic T-cell activation and signaling.